CVS Health Corp (CVS) Shares Surge 3.2% -- What GF Score of 79 T
CVS Health Corp (CVS) shares rose 3.2% to $90.39 on October 14, 2026. GuruFocus values the stock at $78.93, indicating a 14.5% overvaluation. CVS has a GF Score of 79/100, with strengths in profitability and momentum but concerns about growth. Insiders sold $323.7 million in stock over the past year, with no purchases. The P/E ratio is 23.9x, above its 5-year median of 17.6x.
How this was made
The 30-second read
Why it matters
The article emphasizes overvaluation and insider selling, which may prompt traders to reassess CVS's risk/reward profile.
Market read
A modest price rise paired with overvaluation metrics and large insider sell‑off suggests limited upside and possible downside.
What to watch
Potential upcoming earnings or dividend announcements could offset the negative sentiment.
Background
GuruFocus provides a proprietary GF Value™ and GF Score™ analysis, highlighting valuation gaps and insider activity.
Ticker impact
CVS shares rose 3.2% to $90.39 on Oct 14, 2026, while insiders sold $323.7 M of stock in the past year and the stock is deemed 14.5% overvalued by GuruFocus.
likely pressure as investors price in overvaluation and insider sell signals
Valuation metrics show the stock is above its intrinsic estimate and insiders have been dumping shares, which typically precedes a pull‑back.
Market effects
Minimal; the health‑care retail sector is not materially affected by CVS's valuation commentary.
None
Low
Counterpoint
Some investors may view the 3.2% rally as a short‑term momentum play despite overvaluation.
Key entities
- CompanyCVS Health Corp
U.S. health‑care retailer and pharmacy chain.
